Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis : a case-control and exploratory study
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
OBJECTIVES: GCA is a large vessel vasculitis for which triggering factors remain unknown. Clonal haematopoiesis (CH) was associated with atherosclerosis through the induction of inflammation in myeloid cells, and data suggest that CH expansion and inflammation may support each other to induce a pro-inflammatory loop. Our objective was to describe the impact of JAK2p.V617F-mutated myeloproliferative neoplasms (MPNs) on GCA and to screen MPN-free patients for CH mutations.
METHODS: We performed a retrospective case-control study comparing the characteristics of 21 GCA patients with MPN and 42 age- and gender-matched GCA patients without MPN. Also, 18 GCA patients were screened for CH through next-generation sequencing (NGS).
RESULTS: The most frequent associated MPN was essential thrombocythaemia (ET; n = 11). Compared with controls, GCA patients with MPN had less-frequent cephalic symptoms (71.4 vs 97.6%; P = 0.004) and higher platelet counts at baseline [485 × 109/l (interquartile range 346-586) vs 346 (296-418); P = 0.02]. There was no difference between groups for other clinical features. Overall survival was significantly shorter in patients with MPN compared with controls [hazard ratio 8.2 (95% CI 1.2, 56.6); P = 0.03]. Finally, screening for CH using NGS in 15 GCA patients without MPN revealed CH in 33%.
CONCLUSION: GCA patients with MPN display higher platelet counts and shorter overall survival than controls. This association is not fortuitous, given the possible pathophysiological relationship between the two diseases. CH was found in one-third of GCA patients, which may be higher than the expected prevalence for a similar age, and should be confirmed in a larger cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 61(2022), 2 vom: 02. Feb., Seite 775-780 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Papo, Matthias [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clonal haematopoiesis |
|---|
| Anmerkungen: |
Date Completed 09.03.2022 Date Revised 09.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/keab337 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323911471 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323911471 | ||
| 003 | DE-627 | ||
| 005 | 20231225185207.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keab337 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323911471 | ||
| 035 | |a (NLM)33836046 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Papo, Matthias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis |b a case-control and exploratory study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2022 | ||
| 500 | |a Date Revised 09.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVES: GCA is a large vessel vasculitis for which triggering factors remain unknown. Clonal haematopoiesis (CH) was associated with atherosclerosis through the induction of inflammation in myeloid cells, and data suggest that CH expansion and inflammation may support each other to induce a pro-inflammatory loop. Our objective was to describe the impact of JAK2p.V617F-mutated myeloproliferative neoplasms (MPNs) on GCA and to screen MPN-free patients for CH mutations | ||
| 520 | |a METHODS: We performed a retrospective case-control study comparing the characteristics of 21 GCA patients with MPN and 42 age- and gender-matched GCA patients without MPN. Also, 18 GCA patients were screened for CH through next-generation sequencing (NGS) | ||
| 520 | |a RESULTS: The most frequent associated MPN was essential thrombocythaemia (ET; n = 11). Compared with controls, GCA patients with MPN had less-frequent cephalic symptoms (71.4 vs 97.6%; P = 0.004) and higher platelet counts at baseline [485 × 109/l (interquartile range 346-586) vs 346 (296-418); P = 0.02]. There was no difference between groups for other clinical features. Overall survival was significantly shorter in patients with MPN compared with controls [hazard ratio 8.2 (95% CI 1.2, 56.6); P = 0.03]. Finally, screening for CH using NGS in 15 GCA patients without MPN revealed CH in 33% | ||
| 520 | |a CONCLUSION: GCA patients with MPN display higher platelet counts and shorter overall survival than controls. This association is not fortuitous, given the possible pathophysiological relationship between the two diseases. CH was found in one-third of GCA patients, which may be higher than the expected prevalence for a similar age, and should be confirmed in a larger cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clonal haematopoiesis | |
| 650 | 4 | |a giant cell arteritis | |
| 650 | 4 | |a myeloproliferative neoplasm | |
| 650 | 7 | |a JAK2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Janus Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Friedrich, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Delaval, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Boysson, Hubert de |e verfasserin |4 aut | |
| 700 | 1 | |a Viallard, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Bachmeyer, Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Sené, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Duffau, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Contis, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Agard, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Gombert, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Puyade, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Foucher, Aurélie |e verfasserin |4 aut | |
| 700 | 1 | |a Alary, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Danlos, François-Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Régent, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Mouthon, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Guillevin, Loïc |e verfasserin |4 aut | |
| 700 | 1 | |a Samson, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Kosmider, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Terrier, Benjamin |e verfasserin |4 aut | |
| 700 | 0 | |a French Vasculitis Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 61(2022), 2 vom: 02. Feb., Seite 775-780 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:2 |g day:02 |g month:02 |g pages:775-780 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keab337 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e 2 |b 02 |c 02 |h 775-780 | ||